This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Nutriband and Kindeva Drug Delivery have demonstrated enhanced the abuse deterrence kinetics of Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system. Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating can be manufactured using standard commercial transdermal manufacturing processes, which is critical to the success of the product development program. The next step is to select the final product configuration and perform technology transfer from Kindeva’s R&D facility to its world-class transdermal commercial manufacturing site in Northridge, Calif.
AVERSA™ Fentanyl combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).
“We are encouraged by the progress we have made working with the team at Kindeva Drug Delivery who have brought their proven experience in the development of transdermal drug delivery systems to bear on this effort,” says Gareth Sheridan, CEO, Nutriband. “To our knowledge, we will be the first to develop a commercial manufacturing process for an abuse-deterrent transdermal patch. We look forward to continued progress toward completion of the technology transfer to the commercial line.”
Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
